Home LiteratureArticle Details
PMID: 21107346 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Nature reviews. Immunology ·Vol. 10 ·No. 12 ·2010-12-00 ·Pages 849-59

Buckner JH

Abstract

A lack of regulatory T (T(Reg)) cells that express CD4, CD25 and forkhead box P3 (FOXP3) results in severe autoimmunity in both mice and humans. Since the discovery of T(Reg) cells, there has been intense investigation aimed at determining how they protect an organism from autoimmunity and whether defects in their number or function contribute to the development of autoimmunity in model systems. The next phase of investigation - that is, to define the role that defects in T(Reg) cells have in human autoimmunity - is now underway. This Review summarizes our progress so far towards understanding the role of CD4(+)CD25(+)FOXP3(+) T(Reg) cells in human autoimmune diseases and the impact that this knowledge might have on the diagnosis and treatment of these diseases.

MeSH Terms
Animals Autoimmune Diseases/diagnosis,immunology,therapy CD4 Antigens/metabolism Forkhead Transcription Factors/metabolism Humans Inflammatory Bowel Diseases/immunology Interleukin-2 Receptor alpha Subunit/metabolism Mice Psoriasis/immunology T-Lymphocytes, Regulatory/immunology
Chemicals
CD4 Antigens FOXP3 protein, human Forkhead Transcription Factors Interleukin-2 Receptor alpha Subunit
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Buckner Jane Hoyt
Translational Research Program, Benaroya Research Institute, 1201 9th Avenue, Seattle, Washington 98101, USA. jbuckner@benaroyaresearch.org
References (119)
119 references, click to expand
  1. Special regulatory T-cell review: Regulatory T cells and the intestinal tract--patrolling the frontier.
    Immunology. 2008 Jan;123(1):6-10 PMID: 18154611
  2. The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival.
    J Immunol. 2010 Jun 15;184(12):7247-56 PMID: 20483763
  3. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression.
    Gastroenterology. 2009 Apr;136(4):1308-16, e1-3 PMID: 19192480
  4. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance.
    Lupus. 2008 Apr;17(4):289-94 PMID: 18413409
  5. The development and function of regulatory T cells.
    Cell Mol Life Sci. 2009 Aug;66(16):2603-22 PMID: 19390784
  6. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop.
    Ann N Y Acad Sci. 2006 Oct;1079:9-18 PMID: 17130526
  7. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis.
    J Clin Invest. 2006 Dec;116(12):3252-7 PMID: 17099776
  8. How regulatory T cells work.
    Nat Rev Immunol. 2008 Jul;8(7):523-32 PMID: 18566595
  9. Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus.
    Clin Exp Immunol. 2008 Aug;153(2):182-7 PMID: 18505426
  10. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus.
    Immunology. 2009 Jun;127(2):196-205 PMID: 18800986
  11. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.
    Int Immunol. 2007 Jun;19(6):785-99 PMID: 17545278
  12. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo.
    J Exp Med. 2009 Aug 31;206(9):1853-62 PMID: 19667061
  13. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway.
    J Immunol. 2009 Jun 1;182(11):6763-70 PMID: 19454671
  14. The role of immune system in the pathogenesis of psoriasis.
    J Invest Dermatol. 1990 Nov;95(5 Suppl):32S-34S PMID: 16788627
  15. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.
    Eur J Immunol. 2001 Apr;31(4):1247-54 PMID: 11298351
  16. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.
    J Clin Immunol. 2010 Jan;30(1):80-9 PMID: 19936899
  17. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.
    Blood. 2007 Aug 15;110(4):1225-32 PMID: 17449799
  18. Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients.
    Dermatology. 2009;219(3):250-8 PMID: 19752528
  19. Control of regulatory T cell development by the transcription factor Foxp3.
    Science. 2003 Feb 14;299(5609):1057-61 PMID: 12522256
  20. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity.
    Immunol Res. 2007;38(1-3):112-21 PMID: 17917016
  21. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Inflamm Bowel Dis. 2010 Aug;16(8):1299-310 PMID: 20196149
  22. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis.
    J Immunol. 2007 Jul 15;179(2):1322-30 PMID: 17617625
  23. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.
    J Exp Med. 1996 Jul 1;184(1):19-29 PMID: 8691133
  24. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.
    J Neuroimmunol. 2006 Nov;180(1-2):178-84 PMID: 17011048
  25. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.
    J Immunol. 2002 Nov 1;169(9):4712-6 PMID: 12391178
  26. MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus.
    Arthritis Rheum. 2005 Apr;52(4):1180-4 PMID: 15818683
  27. Global natural regulatory T cell depletion in active systemic lupus erythematosus.
    J Immunol. 2005 Dec 15;175(12):8392-400 PMID: 16339581
  28. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.
    J Immunol. 2009 Sep 1;183(5):3170-6 PMID: 19648274
  29. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.
    J Leukoc Biol. 2004 May;75(5):785-91 PMID: 14694186
  30. Decrease of regulatory T cells in patients with systemic lupus erythematosus.
    Ann Rheum Dis. 2006 Apr;65(4):553-4 PMID: 16531555
  31. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.
    Diabetes. 2005 May;54(5):1407-14 PMID: 15855327
  32. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.
    J Immunol. 2008 Nov 15;181(10):7350-5 PMID: 18981158
  33. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.
    Diabetes. 2010 Feb;59(2):407-15 PMID: 19875613
  34. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.
    J Exp Med. 2004 Jun 7;199(11):1455-65 PMID: 15184499
  35. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.
    Immunol Rev. 2006 Aug;212:8-27 PMID: 16903903
  36. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.
    J Clin Immunol. 2004 Mar;24(2):155-61 PMID: 15024182
  37. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors.
    Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19857-62 PMID: 19073938
  38. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus.
    Immunology. 2006 Feb;117(2):280-6 PMID: 16423064
  39. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease.
    Clin Immunol. 2007 Dec;125(3):281-90 PMID: 17897887
  40. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21.
    J Immunol. 2008 Apr 15;180(8):5393-401 PMID: 18390721
  41. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.
    Gastroenterology. 2005 Jun;128(7):1868-78 PMID: 15940622
  42. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood.
    Rheumatology (Oxford). 2006 Oct;45(10):1210-7 PMID: 16571607
  43. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in Psoriasis.
    Dermatology. 2006;213(2):111-7 PMID: 16902287
  44. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.
    Science. 2003 Feb 14;299(5609):1033-6 PMID: 12532024
  45. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.
    Nat Med. 2007 Apr;13(4):423-31 PMID: 17384649
  46. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.
    Arthritis Rheum. 2008 Mar;58(3):801-12 PMID: 18311820
  47. Identification of regulatory T cells in systemic lupus erythematosus.
    Autoimmun Rev. 2009 Mar;8(5):426-30 PMID: 19185065
  48. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells.
    Immunol Rev. 2001 Aug;182:207-14 PMID: 11722636
  49. Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis.
    Br J Dermatol. 2010 Apr;162(4):895-7 PMID: 20199542
  50. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
    Nat Immunol. 2003 Apr;4(4):330-6 PMID: 12612578
  51. Regulatory T cells overturned: the effectors fight back.
    Immunology. 2009 Apr;126(4):466-74 PMID: 19278420
  52. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity.
    Inflamm Bowel Dis. 2006 Jun;12(6):447-56 PMID: 16775488
  53. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells.
    J Immunol. 2004 Mar 15;172(6):3580-9 PMID: 15004159
  54. FOXP3+ regulatory T cells in the human immune system.
    Nat Rev Immunol. 2010 Jul;10(7):490-500 PMID: 20559327
  55. Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells.
    J Immunol. 2005 Jul 15;175(2):641-5 PMID: 16002658
  56. Decreased FOXP3 levels in multiple sclerosis patients.
    J Neurosci Res. 2005 Jul 1;81(1):45-52 PMID: 15952173
  57. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids.
    Ann Rheum Dis. 2006 Nov;65(11):1512-7 PMID: 16606650
  58. CD4+CD25high regulatory T cells in human autoimmune diabetes.
    J Autoimmun. 2005 Feb;24(1):55-62 PMID: 15725577
  59. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression.
    J Immunol. 2008 May 1;180(9):6411-20 PMID: 18424765
  60. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.
    Clin Exp Immunol. 2007 Mar;147(3):412-8 PMID: 17302889
  61. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris.
    Br J Dermatol. 2010 Jul;163(1):48-56 PMID: 20222932
  62. FOXP3 promoter demethylation reveals the committed Treg population in humans.
    PLoS One. 2008 Feb 20;3(2):e1612 PMID: 18286169
  63. Multiple immuno-regulatory defects in type-1 diabetes.
    J Clin Invest. 2002 Jan;109(1):131-40 PMID: 11781358
  64. Regulatory T cells and transplantation tolerance.
    Hum Immunol. 2006 Oct;67(10):765-76 PMID: 17055353
  65. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.
    J Clin Invest. 2003 Nov;112(9):1437-43 PMID: 14597769
  66. Epigenetic control of the foxp3 locus in regulatory T cells.
    PLoS Biol. 2007 Feb;5(2):e38 PMID: 17298177
  67. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus.
    Arthritis Rheum. 2008 Jul;58(7):2120-30 PMID: 18576316
  68. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse.
    Nat Genet. 2001 Jan;27(1):68-73 PMID: 11138001
  69. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity.
    Clin Immunol. 2010 Apr;135(1):108-17 PMID: 20006553
  70. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes.
    Clin Exp Immunol. 2008 Dec;154(3):353-9 PMID: 19037920
  71. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis.
    Clin Exp Immunol. 2005 May;140(2):360-7 PMID: 15807863
  72. Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action.
    Clin Exp Immunol. 2008 Feb;151(2):326-33 PMID: 18190460
  73. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.
    J Immunol. 2007 Feb 15;178(4):2579-88 PMID: 17277168
  74. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Immunology. 2008 Oct;125(2):178-83 PMID: 18422560
  75. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.
    J Med Genet. 2002 Aug;39(8):537-45 PMID: 12161590
  76. Thymic development and peripheral homeostasis of regulatory T cells.
    Curr Opin Immunol. 2007 Apr;19(2):176-85 PMID: 17306520
  77. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus.
    Scand J Immunol. 2004 Feb;59(2):198-202 PMID: 14871297
  78. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.
    Diabetes. 2005 Jan;54(1):92-9 PMID: 15616015
  79. Allograft rejection mediated by memory T cells is resistant to regulation.
    Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19954-9 PMID: 18042727
  80. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis.
    Dig Dis Sci. 2006 Apr;51(4):677-86 PMID: 16614988
  81. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells.
    Diabetes. 2005 May;54(5):1415-22 PMID: 15855328
  82. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.
    J Exp Med. 2004 Aug 2;200(3):277-85 PMID: 15280421
  83. Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris.
    J Dermatol Sci. 2008 Sep;51(3):200-3 PMID: 18562180
  84. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells.
    Eur J Immunol. 2002 Jun;32(6):1621-30 PMID: 12115645
  85. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
    Immunity. 2008 May;28(5):687-97 PMID: 18468463
  86. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.
    J Immunol. 2004 Jun 1;172(11):6519-23 PMID: 15153463
  87. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development.
    J Immunol. 2003 Oct 15;171(8):4040-7 PMID: 14530324
  88. Intestinal lamina propria retaining CD4+CD25+ regulatory T cells is a suppressive site of intestinal inflammation.
    J Immunol. 2007 Apr 15;178(8):4937-46 PMID: 17404275
  89. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.
    J Exp Med. 2004 Apr 5;199(7):971-9 PMID: 15067033
  90. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.
    J Immunol. 2003 Apr 15;170(8):3939-43 PMID: 12682220
  91. Multiple sclerosis: a complicated picture of autoimmunity.
    Nat Immunol. 2007 Sep;8(9):913-9 PMID: 17712344
  92. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
    Autoimmunity. 2010 Jun;43(4):325-33 PMID: 20298123
  93. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2007 Jan;182(1-2):204-11 PMID: 17157927
  94. Analysis of islet inflammation in human type 1 diabetes.
    Clin Exp Immunol. 2009 Feb;155(2):173-81 PMID: 19128359
  95. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells.
    Blood. 2006 Jul 1;108(1):253-61 PMID: 16537805
  96. Quantification of regulatory T cells in patients with systemic lupus erythematosus.
    J Autoimmun. 2003 Nov;21(3):273-6 PMID: 14599852
  97. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes.
    J Immunol. 2010 Oct 1;185(7):3814-8 PMID: 20810982
  98. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis.
    J Clin Invest. 2008 Oct;118(10):3411-9 PMID: 18769633
  99. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.
    J Clin Invest. 1995 Jan;95(1):317-27 PMID: 7529261
  100. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis.
    J Immunol. 2006 Nov 1;177(9):5852-60 PMID: 17056509
  101. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease.
    Clin Exp Immunol. 2005 Sep;141(3):549-57 PMID: 16045746
  102. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.
    Arch Neurol. 2009 Apr;66(4):471-9 PMID: 19364932
  103. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis.
    Clin Exp Immunol. 2008 Jul;153(1):44-55 PMID: 18505436
  104. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis.
    Arthritis Rheum. 2003 May;48(5):1452-60 PMID: 12746920
  105. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.
    J Immunol. 2005 Jan 1;174(1):164-73 PMID: 15611238
  106. Regulatory T cells in patients with systemic lupus erythematosus.
    J Autoimmun. 2006 Sep;27(2):110-8 PMID: 16890406
  107. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    J Immunol. 1995 Aug 1;155(3):1151-64 PMID: 7636184
  108. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis.
    Cell Immunol. 2008 May-Jun;253(1-2):92-101 PMID: 18649874
  109. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.
    J Exp Med. 2006 Jul 10;203(7):1701-11 PMID: 16818678
  110. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Immunology. 2008 Jan;123(1):79-89 PMID: 17897326
  111. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.
    J Immunol. 2010 Apr 1;184(7):3433-41 PMID: 20181882
  112. CD4+CD25high regulatory cells in human peripheral blood.
    J Immunol. 2001 Aug 1;167(3):1245-53 PMID: 11466340
  113. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
    Diabetes. 2007 Mar;56(3):604-12 PMID: 17327427
  114. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
    Eur J Immunol. 2005 Nov;35(11):3343-52 PMID: 16206232
  115. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.
    Inflamm Bowel Dis. 2007 Feb;13(2):191-9 PMID: 17206665
  116. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis.
    Eur J Immunol. 2003 Jan;33(1):215-23 PMID: 12594850
  117. Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis.
    Arthritis Rheum. 2007 Mar;56(3):732-42 PMID: 17328044
  118. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.
    Immunity. 2009 Jun 19;30(6):899-911 PMID: 19464196
  119. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.
    Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19396-401 PMID: 19036923
Article Info
Journal
Nature reviews. Immunology
Abbr.
Nat Rev Immunol
ISSN
1474-1741
DOI
10.1038/nri2889
Email
jbuckner@benaroyaresearch.org
Published
2010-12-00
Pages
849-59
Language
English
Region
England
NLM ID
101124169
PMCID
PMC3046807
Subset
IM
Grants
NIDDK NIH HHS · R01 DK072457-02 · United States
NIDDK NIH HHS · R01 DK072457-03 · United States
NIDDK NIH HHS · R01 DK072457-05 · United States
NIDDK NIH HHS · R01 DK072457-04 · United States
NIDDK NIH HHS · R01 DK072457 · United States
External Links
PubMed source DOI: 10.1038/nri2889 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2